Table 4.

Biodistribution of ^99mTc-RfD-Lys-(Arg¹¹)CCMSH in B16/F1 melanoma-bearing C57 mice. The data was presented as percent injected dose/gram or as percent injected dose (mean ± SD, n=4).

Tissue	0.5 h	2 h	4 h	24 h	2 h NDP Blockade
		Percent injected dose/gram (%ID/g)
Tumor	9.56 ± 2.36	12.68 ± 2.39	15.01 ± 4.40	7.19 ± 1.02	2.82 ± 0.48*
Brain	0.16 ± 0.01	0.04 ± 0.01	0.03 ± 0.02	0.01 ± 0.01	0.04 ± 0.01
Blood	7.85 ± 2.12	1.01 ± 0.11	0.45 ± 0.12	0.06 ± 0.01	0.74 ± 0.01
Heart	2.67 ± 0.89	0.50 ± 0.17	0.45 ± 0.12	0.21 ± 0.08	0.60 ± 0.09
Lung	6.44 ± 1.81	2.73 ± 1.08	1.19 ± 0.44	0.47 ± 0.22	1.83 ± 0.35
Liver	6.59 ± 0.61	5.29 ± 1.30	4.47 ± 1.63	4.57 ± 0.45	3.77 ± 1.53
Skin	4.87 ± 0.41	1.25 ± 0.29	0.85 ± 0.11	0.34 ± 0.08	1.30 ± 0.43
Spleen	2.98 ± 1.23	1.26 ± 0.45	0.86 ± 0.19	0.76 ± 0.08	0.93 ± 0.36
Stomach	3.37 ± 1.40	2.71 ± 0.75	1.86 ± 0.46	0.51 ± 0.11	4.49 ± 0.85
Kidneys	103.75 ± 11.26	111.54 ± 10.19	104.95 ± 8.06	73.05 ± 9.87	111.34 ± 12.41
Muscle	0.45 ± 0.12	0.04 ± 0.03	0.02 ± 0.01	0.04 ± 0.03	0.03 ± 0.01
Pancreas	0.48 ± 0.16	0.38 ± 0.15	0.18 ± 0.03	0.05 ± 0.01	0.31 ± 0.11
Bone	0.07 ± 0.06	0.43 ± 0.07	0.15 ± 0.03	0.19 ± 0.14	0.38 ± 0.30
		Percent injected dose (%ID)
Intestines	2.49 ± 0.60	2.58 ± 1.38	3.18 ± 1.08	0.82 ± 0.14	2.65 ± 1.53
Urine	22.56 ± 12.86	44.49 ± 12.39	50.50 ± 8.66	72.74 ± 7.36	54.88 ± 2.72
		Uptake ratio of tumor/normal tissue
Tumor/Blood	1.22	12.55	33.36	119.83	3.81
Tumor/Kidneys	0.09	0.11	0.14	0.10	0.03
Tumor/Lung	1.48	4.64	12.61	15.30	1.54
Tumor/Liver	1.45	2.40	3.36	1.57	0.75
Tumor/Muscle	21.24	317.00	750.50	179.75	94.00

^*p<0.05 (p=0.002) for determining the significance of differences in tumor and kidney uptake between ^99mTc-RfD-Lys-(Arg¹¹)CCMSH with or without NDP-MSH peptide blockade at 2 h post-injection.